Many medical device manufacturers have found themselves caught in a trap where they have received NUB status 1 and/or 4 but the hospitals were rejected during the negotiation with the insurance companies.
Based on the experience of the hundreds of projects we have delivered, we have developed a new solution to provide a comprehensive overview of your reimbursement situation including information (op
We are happy to announce that new member of Synergus team is Dr. Huseyin Aytug. Dr. Huseyin has B.A in Economics with distinction from Marmara University in Istanbul, Turkey, M.A (2010) and Ph.D. (2013) both in International Economics from University of California-Santa Cruz, US.
Germany introduced a new legislation in 2016 that requires an assessment of the potential benefit of new methods based on high-risk medical devices before they can receive innovation funding (NUB).
We are happy to announce that Günay Karli has joined our team. He is extending our current expertise in real world data.